Table 2.
Detailed overview of treatment with biological agents in 28 flares of 13 pediatric patients
| Target | Drug | Dose | Pustule cleareance (day) | Clinical improvement number of patients/total number treated | Clinical response type | Concomitant systemic treatment | Treatment duration (months) | Reference |
|---|---|---|---|---|---|---|---|---|
| TNF-a | ETA | NA | NA | 1/1 | PR | MTX | 4 | [19] |
| 0.4 mg/kg twice per wk | NA | 1/1 | CR* | NA | 7 | [15] | ||
| 12.5 mg/wk | 35 | 1/1 | CR | ACI 1 mg/kg/d | 6 | [10] | ||
| NA | NA | 0/1 | NR | ACI | 7 | [3] | ||
| 0.8 mg/kg/wk | NA | 0/1 | NR | – | 3 | [6] | ||
| ADA | 20 mg /every 2 wk | NA | 0/1 | NR | NA | NA | [15] | |
| NA | NA | 1/1 | CR** | NA | 26 | [8] | ||
| NA | NA | 0/1 | NR | NA | 1 | [3] | ||
| 20 mg every wk | 7 | 1/1 | CR | – | 8 | Patient reported here | ||
| IFL | 100 mg in 2 wk. interval, in total 2 infusions (3,3 mg/kg) | 14 | 1/1 | CR** | - | 0,5*** | [28] | |
| 5 mg/kg | NA | 1/1 | CR** | NA | 9 | [8] | ||
| NA | NA | 1/1 | CR | NA | 1 | [26] | ||
| IL-1 | ANA | 4 mg/kg/d | 7 | 1/1 | CR | – | 2 | [31] |
| 5 mg/kg/d | NA | 0/1 | NR | NA | 3 | [5] | ||
| 100 mg/d | NA | 0/1 | NR | NA | 3 days | [8] | ||
| 6 mg/kg/d | NA | 0/1 | NR | NA | NA | [19] | ||
| 5 mg/kg/d | NA | 0/1 | NR | NA | NA | [10] | ||
| NA | NA | 0/2 | NR | NA | 2/0,2 | [3] | ||
| 6 mg/kg/d | Partial | 1/1 | PR | – | 36 | [6] | ||
| CAN | 3 mg/kg/d every 8 wks | NA | 0/1 | NR | NA | NA | [5] | |
| IL12/23 | UST | NA | NA | 1/1 | CR* | NA | 31 | [8] |
|
Pat 1: 1.5 mg/kg every 2 mths Pat 2: 1 mg/kg every 2 mths |
NA “weeks” | 2/2 | CR CR | IVIG- | 155 | [3] | ||
| 0.75 mg/kg every 3mths | NA | 1/1 | CR | – | 12 | [6] | ||
| IL-17 | SEC | 150 mg/wkly ervery 4 wks | 1 | 1/1 | CR | MTX 5 mg/wk | 12 | [8] |
| 75 mg/wk | NA | 1/1 | CR** | PRED 2.5 mg/d | 2 | [19] | ||
| 150 mg mthly | 14 | 1/1 | CR** | – | 8**** | [15] | ||
| 300 mg every 4 wks, initially 5 doses 300 mg wkly | 2 | 1/1 | CR** | – | 6 | [24] |
Abbr. ADA-adalimumab, ANA-anakinra, CANA-canakinumab, CR-complete response, ETA-etanercept, IFL-infliximab, MP-methylprednisolone, NA-not available, NR-no response, PRED-prednisolone, PR-partial response, SEC-Secukinumab, UST-ustekinumab, * secondary failure after 7 months, changed to SEC **mild relaps, *** 21 months of follow-up interval after cessation of treatment, **** 4 months of follow-up interval after cessation of treatment.